KAKhusru Asadullah

Khusru Asadullah

*This is an algorithmically generated author record based on publicly available information.

Khusru Asadullah has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Soluble Receptors of the Interleukin-10 Family of Cytokines: Interleukin-22 Receptor Alpha 2

    by R. Sabat, E. Wallace, K. Asadullah, W. Sterry, H.-D. Volk, K. Wolk

    The interleukin (IL)-10 family of cytokines comprising IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28α, IL- 28β, and IL-29 uses receptors of the cytokine receptor family class 2. Here we review the current knowledge about IL-22 receptor-α2 (IL-22Rα2) which is the first known soluble receptor of that cytokine family. The human IL-22Rα2-encoding gene includes seven exons and is located on chromosome 6 between the genes for interferon-γ receptor-1 and IL-20 receptor- 1. The products of this gene are three different mRNA splice variants. The genes for the mouse and rat IL-22Rα2 have a very similar genomic location and structure to those in humans, although they lack the human exon 4 counterpart and produce only one variant which corresponds to the human variant 2. Irrespective of the species and splice variant, IL- 22Rα2 lacks any sequence for a transmembrane or an intracellular part, and is a secreted protein. It is particularly expressed in the placenta, the mammary glands, and the lymph nodes but also in the gastrointestinal system, the lungs, the skin, and other lymphatic organs. It seems, however, that the variants 3 and 1 are more restricted in their expression. Variant 2 binds to and inhibits the activity of IL-22 in vitro, whereas the specificity of variants 3 and 1 has not been identified. The discovery of IL-22Rα2 represents a first step towards understanding the regulatory network regarding the action of IL-22 and perhaps of other members of the IL-10 family. It also may open up new ways for targeting the action of these cytokines for therapeutic interests.

  • Glucocorticoid therapy‐induced skin atrophy

    by Stefanie Schoepe, Heike Schäcke, Ekkehard May, Khusru Asadullah

    Abstract: Glucocorticoids (GCs) are highly effective for the topical treatment of inflammatory skin diseases. Their long‐term use, however, is often accompanied by severe and partially irreversible adverse effects, with atrophy being the most prominent limitation. Progress in the understanding of GC‐mediated molecular action as well as some advances in technologies to determine the atrophogenic potential of compounds has been made recently. It is likely that the detailed mechanisms of GC‐induced skin atrophy will be discovered andin vitromodels for the reliable prediction of atrophy will be established in the foreseeable future. This knowledge will not only facilitate safety profiling of established drugs but will also foster further drug discovery by improving compound characterization processes. New insights into GC modes of action will guide optimization strategies aiming at novel GC receptor ligands with improved effect/side effect profile.


  • Psoriasis, Molecular Basis

    by Khusru Asadullah, Wolfram Sterry

  • Zytokine und kutane Lymphome

    by K. Asadullah, W.-D. Döcke, M. Friedrich, H.-D. Volk, W. Sterry

    Zytokine spielen als wichtige Botenstoffe des Immunsystems eine große Rolle in der Pathogenese von kutanen Lymphomen. Ihre Bedeutung resultiert aus autokrinen, parakrinen und endogenen Effekten. In zahlreichen Untersuchungen konnte die Überexpression einzelner Zytokine bei verschiedenen kutanen Lymphomen gezeigt werden. Dabei wurden auch stadienabhängige Verschiebungen im Zytokinprofil, z. B. bei der Mycosis fungoides (MF), beobachtet. Es existieren zahlreiche Hinweise, dass eine gestörte Zytokinexpression bei kutanen Lymphomen für die Tumorprogression verantwortlich ist. Dieses resultiert aus einer Stimulation der Proliferation der malignen Zellen und/oder der Unterdrückung einer adäquaten Anti-Tumor-Immunantwort. Darüber hinaus können Zytokine für eine Reihe von Immunphänomenen verantwortlich gemacht werden, wie z. B. den Epidermotropismus maligner Zellen, die Eosinophilie und die erhöhten Plasma IgE-Spiegel, welche bei Patienten mit kutanen T-ZellLymphomen in fortgeschrittenem Stadium gefunden werden. Untersuchungen zur Zytokinexpression und ihrer Rolle bei kutanen Lymphomen können die Basis für neue Therapieansätze durch Intervention in das Zytokinnetzwerk bilden. Due to their essential role as mediators of the immune system, cytokines play a major role in the pathogenesis of cutaneous lymphomas. Their impact results from autocrine, paracrine and endogene effects. In numerous investigations, the overexpression of several cytokines has been demonstrated in different entities of cutaneous lymphomas. Stage dependent shifts of the cytokine profile have been observed, e. g. in mycosis fungoides. There are several lines of evidence that a disturbed cytokine expression may be responsible for tumor progression in cutaneous lymphomas. This results from the stimulation of malignant cell proliferation and/or the suppression of an adequate anti-tumor immune response. Moreover, cytokines seem to be responsible for some immuno-phenomena such a epidermotropism of malignant cells, eosinophilia and enhanced IgE-plasma levels, which are typical in patients with advanced cutaneous T cell lymphomas. Investigations of cytokine expression and their role in cutaneous lymphomas may contribute to the development of novel therapeutic strategies by intervention within the cytokine network.

  • Interleukin-10: An Important Immunoregulatory Cytokine With Major Impact on Psoriasis

    by Khusru Asadullah, Robert Sabat, Markus Friedrich, Hans Dieter Volk, Wolfram Sterry

    Interleukin (IL)-10 is a pluripotent cytokine with effects on numerous cell populations, in particular circulating and resident immune cells as well as epithelial cells. With its potent immunoregulatory capacities its main biological function seems to be the limitation and termination of inflammatory responses. Thus its low level expression found in psoriasis may have pathophysiological relevance for this immune disease. Remarkably, induction of IL-10 expression was found by conventional antipsoriatic therapies, supporting the hypothesis that IL - 10 may be a key cytokine in psoriasis and that application of this cytokine itself may have therapeutic effects. In first clinical trials in patients with established psoriasis IL-10 showed moderate antipsoriatic effects and was well tolerated. Moreover, long term application in psoriatic patients remission showed that IL-10 therapy decreases the incidence of relapse and prolongs the disease free interval. The immunological effects observed during these clinical studies together with in vitro observations suggests that IL-10 exerts its antipsoriatic activity by effects on different cell populations including antigen presenting cells and T-cells (lasting type 1 / type 2 cytokine balance shift), but not trough direct effects on keratinocytes. In conclusion IL-10 seems to have major importance in psoriasis. Further investigations, in particular multicenter, placebo-controlled, double blind trials are required to fully determine whether IL-10 application will become a successful antipsoriatic therapy.


  • Top Cited Papers

    Interleukin-10 Therapy—Review of a New Approach

    by K. Asadullah, W. Sterry, H. D. Volk

    Interleukin (IL)-10 is an important immunoregulatory cytokine produced by many cell populations. Its main biological function seems to be the limitation and termination of inflammatory responses and the regulation of differentiation and proliferation of several immune cells such as T cells, B cells, natural killer cells, antigen-presenting cells, mast cells, and granulocytes. However, very recent data suggest IL-10 also mediates immunostimulatory properties that help to eliminate infectious and noninfectious particles with limited inflammation. Numerous investigations, including expression analyses in patients, in vitro and animal experiments suggest a major impact of IL-10 in inflammatory, malignant, and autoimmune diseases. So IL-10 overexpression was found in certain tumors as melanoma and several lymphomas and is considered to promote further tumor development. Systemic IL-10 release is a powerful tool of the central nervous system to prevent hyperinflammatory processes by activation of the neuro-endocrine axis following acute stress reactions. In contrast, a relative IL-10 deficiency has been observed and is regarded to be of pathophysiological relevance in certain inflammatory disorders characterized by a type 1 cytokine pattern such as psoriasis. Recombinant human IL-10 has been produced and is currently being tested in clinical trials. This includes rheumatoid arthritis, inflammatory bowel disease, psoriasis, organ transplantation, and chronic hepatitis C. The results are heterogeneous. They give new insight into the immunobiology of IL-10 and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target.


  • Keratinocyte unresponsiveness towards interleukin‐10: lack of specific binding due to deficient IL‐10 receptor 1 expression

    by Martina Seifert, Beate H. Gruenberg, Robert Sabat, Peter Donner, Gerald Gruetz, Hans‐Dieter Volk, Kerstin Wolk, Khusru Asadullah

    Whereas the effects of interleukin (IL)‐10 on several epithelial cell types are well established the capability of IL‐10 to target keratinocytes (KC) is still a matter of debate. This, however, is of considerable importance, as IL‐10 is a major anti‐inflammatory, immunosuppressive cytokine with impact on the cutaneous homeostasis. Recently, IL‐10 therapy has been proven to be clinically effective in psoriasis. Response to therapy is associated with normalization of typical parameters of keratinocyte pathology, but it is unclear whether this results from direct or indirect (secondary) effects. The purpose of the present study was to further investigate direct effects of IL‐10 on keratinocytes and to address the reason for potential IL‐10 unresponsiveness using keratinocytes such as the cell line HaCaT as well as primary foreskin keratinocytes. Using real time RT‐PCR we demonstrated that IL‐10 is neither able to induce its typical early gene product suppressor of cytokine signalling (SOCS) 3 nor to modulate the interferone (IFN)‐γ‐induced expression of SOCS 1 and 3. Although flow cytometric analyses showed binding of biotin labelled IL‐10 to HaCaT cells, blocking experiments indicated that this resulted from unspecific binding. Moreover, scatchard plot analyses excluded specific binding to primary KC and HaCaT cells. Finally, real time mRNA analyses and Western blot experiments demonstrated that the absence of any specific binding results from the absence of clear IL‐10R1 (alpha chain) expression, whereas the IL‐10R2 (beta chain) is strongly expressed. Our data indicates that IL‐10 unresponsiveness of keratinocytes could be explained by the lacking of functional IL‐10 receptor expression and suggest that any IL‐10 effects on these cells observed are indirectly mediated.


  • Cytokines: interleukin and interferon therapy in dermatology

    by K. Asadullah, W. Sterry, U. Trefzer

    Cytokines are highly potent biologically active proteins that play an essential role in intercellular communication. They are vital to the mediation and regulation of inflammatory and specific immune reactions as well as to nonimmunological processes. Several cytokines are already used for the treatment of malignant, inflammatory and infectious skin diseases. This in particular includes certain interleukins (ILs) and interferons (IFNs). Whereas some cytokine therapies are already approved and well established, such as IFN-alpha and IL-2 (approved in the USA) for melanoma, others are in the early stages of development and are used in explorative trials (e.g. IL-4 and IL-10 in the treatment of psoriasis). It is likely that some of the new approaches currently under investigation will actually lead to both the registration of new drugs for dermatological treatment, and to supplementation of existing therapeutic options. The aim of this review is to give an overview on the current state of cytokine therapy in dermatology.